The modulation of inflammation by the NF-kB inhibitor (IkB) and its disruption by phosphorylation (p-IkB) in PBMCs was tested in parallel, since inflammation is potentially involved in tumor [29] and AD [30] biology. Here, NFKB1 is linked to neoplasm.